Premium
Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin
Author(s) -
Vaynblat Mikhail,
Shah Himansu R.,
Bhaskaran Dinesh,
Ramdev Geeta,
Davis Wellington J.,
Cunningham Joseph N.,
Chiavarelli Mario
Publication year - 2002
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/s1388-9842(02)00091-0
Subject(s) - enalapril , medicine , heart failure , angiotensin converting enzyme , doxorubicin , cardiology , diastole , hemodynamics , cardiomyopathy , anesthesia , blood pressure , chemotherapy
Aims: The purpose of this study was to determine that the administration of an angiotensin converting enzyme (ACE) inhibitor enalapril would confer protection against doxorubicin‐induced experimental heart failure, and attenuate the development of left ventricular dysfunction. Methods: Seventeen dogs were chronically instrumented with an intracoronary catheter and received doxorubicin weekly for 4 weeks. Animals were assigned to two groups: group 1: untreated heart failure; and group 2: simultaneous enalapril administration (5 mg twice a week). Hemodynamic data were obtained at week 0 and 12. Echocardiography was performed weekly. Results Survival improved with simultaneous enalapril administration (36% in group 1 vs. 100% in group 2, P =0.04). The increase in the left ventricular end‐diastolic pressure was significantly reduced at week 12 (17±1 mmHg in group 1 vs. 9±1 mmHg in group 2, P =0.0042). The fall in left ventricular stroke work index was significantly prevented (52% in group 1 vs. 21% in group 2, P =0.006). The increase in right ventricular end‐diastolic diameter was significantly reduced by enalapril prophylaxis. Conclusion: Simultaneous treatment with enalapril was beneficial in the prevention of doxorubicin‐induced cardiomyopathy.